Mortsel / Belgium, 24 November, 2004
Agfa announced today that it has signed a letter of intent with Medicsight, the UK-based leading developer of medical imaging analysis software, to integrate and distribute its Computer Assisted Reading (CAR) software.
Accordingly, Medicsight's Colon CAR(TM), Lung CAR(TM) and Heart Screen(TM) software will be integrated into Agfa's solutions for radiology and clinical specialties on the global market and Agfa will be granted limited exclusivity to distribute such integrated solutions. Both the research departments of Agfa and Medicsight will work closely together to develop completely integrated solutions, assisting radiologists in detecting and accurately measuring colon polyps, lung lesions and coronary artery calcifications.
"Integrating the Medicsight portfolio in our market-leading solutions fits into our strategy of offering best-of-breed solutions to the radiologist and clinician through intelligent strategic alliances," said Etienne Vanderstokker, Agfa's Head of HE Imaging Technologies. "It's a successful and award-winning strategy that has been fully appreciated by the market and has strengthened Agfa's capability to penetrate new markets and to remain on top of technological innovations."
Medicsight's software Lung CAR and Colon CAR, both of which recently gained FDA clearance will be demonstrated at Agfa's booth during the annual meeting of the RSNA.
"The letter of intent is a major milestone for Medicsight in reaching our goal of being the leading global supplier of medical imaging analysis software," said Paul Samuel, Medicsight CEO. "We look forward to working with Agfa and to integrate our software into their systems. We believe this partnership demonstrates the significant value of the Medicsight software and clearly shows how our software can differentiate existing offerings of imaging companies."
The letter of intent declares that the final agreement will be signed in January 2005.
End of message
About Medicsight
Medicsight is a software development business focused on the medical imaging market. The company is using its core technology to develop automatic detection and analytical tools for clinicians to improve their ability to diagnose and treat disease, initially focusing on three key clinical areas - lung cancer, colon cancer, and coronary heart disease. Medicsight's software will enable earlier and more accurate detection and treatment of suspicious lesions, which can save lives and reduce healthcare costs. Headquartered in London, Medicsight employs more than 60 people and has offices in the UK, USA and China Product and company information can be found on www.medicsight.com.
About Agfa
The Agfa-Gevaert Group is one of the world's leading imaging companies. Agfa develops, manufactures and markets analogue and digital systems, intended mainly for the graphics industry and the healthcare markets. Agfa's headquarters are in Mortsel, Belgium. The company is active in 40 countries and has agents in another 100 countries throughout the world. Together they achieved a turnover of 4,215 million euros in 2003.
Product and company information can be found on Agfa's home page on the World Wide Web at: www.agfa.com.
Agfa, the Agfa rhombus, IMPAX and See More. Do More. are trademarks of Agfa-Gevaert N.V., Belgium or its affiliates. All rights reserved.
Contacts:
Geertrui De Smet
Global PR Manager HealthCare
tel.: +32 (0) 3 444 73 06
fax: +32 (0) 3 444 72 85
e-mail: geertruidesmet@agfapress.com
Johan Jacobs
Corporate Press Relations Manager
tel.: +32 (0)3 444 80 15
fax: +32 (0)3 444 74 85
e-mail: johan.jacobs@agfa.com
